A study offers much needed information on the rate of infant mortality in infants who have prenatal exposure to opioids.
With the continuing opioid epidemic, it’s increasingly necessary to understand the impact that exposure to opioids has on infants, as knowledge on the subject thus far has been sparse. A report in JAMA Pediatrics offers much needed information.1
Investigators conducted a retrospective cohort study of mother-infant pairs that linked health care claims to vital records for births between January 2010 to December 2014. A pair was included in the study if the infant was born in Texas at 22 to 43 weeks’ gestational age and the mother was aged 15 to 44 years and was insured by Texas’s Medicaid program. Primary exposure was prenatal exposure to opioids and infants were stratified by the presence or absence of a diagnosis of neonatal opioid withdrawal syndrome during the hospitalization at birth.
A total of 1,129,032, mother-infant pairs were included in the study. There were 7207 pairs who had prenatal opioid exposure of which 4238 had a neonatal opioid withdrawal syndrome diagnosis (mean birth weight, 2851 [624] g) and 2969 who didn’t have a diagnosis (mean birth weight, 2971 [639] g). The infant mortality was 6 per 1000 live births in the reference group, 11 per 1000 live births for infants with neonatal opioid withdrawal syndrome, and 20 per 1000 live births for infants exposed to opioids who were not diagnosed with neonatal opioid withdrawal syndrome (P < .001). After adjusting for neonatal and maternal characteristics, the mortality in infants with a neonatal opioid withdrawal syndrome diagnosis didn’t significantly differ from the reference population (odds ratio, 0.82; 95% CI, 0.58-1.14), whereas the mortality odds in opioid-exposed infant who didn’t have a neonatal opioid withdrawal syndrome diagnosis was 72% greater than the reference population (odds ratio, 1.72; 95% CI, 1.25-2.37).
The investigators concluded that infants exposed to opioids were at increased risk of mortality and the treatment and other supports given to infants with neonatal opioid withdrawal syndrome could be protective. They concluded interventions are necessary, regardless of the severity of the withdrawal from opioids in the infant.
Reference
1. Leyenaar J, Schaefer A, Wasserman J, Moen E, O'Malley J, Goodman D. Infant mortality associated with prenatal opioid exposure. JAMA Pediatr. April 12, 2021. Epub ahead of print. doi:10.1001/jamapediatrics.2020.6364
Having "the talk" with teen patients
June 17th 2022A visit with a pediatric clinician is an ideal time to ensure that a teenager knows the correct information, has the opportunity to make certain contraceptive choices, and instill the knowledge that the pediatric office is a safe place to come for help.
Stress ulcer prophylaxis does not provide prevention of gastrointestinal bleeding in neonates
December 4th 2023In a poster abstract presented at the American Society of Health-System Pharmacists Midyear Clinical Meeting & Exhibition held in Anaheim, California, stress ulcer prophylaxis (SUP) did not appear to provide benefit for prevention of gastrointestinal bleeding and did not increase SUP-associated adverse effects.
Hematocrit levels in newborns: EPP vs DCC study reveals surprising findings
November 15th 2023A recent study in JAMA Network Open investigates the impact of extrauterine placental perfusion versus delayed cord clamping on hematocrit levels in newborns, shedding light on potential alternatives for optimizing infant outcomes during birth.
Preterm infant HRQOL: Long-term impacts and determinants
October 21st 2023A recent study was highlighted at the 2023 American Academy of Pediatrics National Conference & Exhibition that shed light on the long-term impact of very preterm birth on the health-related quality of life (HRQOL) of infants and identified key determinants.